Paclitaxel
Ovarian Cancer- IV (Adults): Previously untreated patients: 175 mg/m2 over 3 hr every 3 wk or 135 mg/m2 over 24 hr every 3 wk, followed by cisplatin; Previously treated patients: 135 mg/m2 or 175 mg/m2 over 3 hr every 3 wk. Breast Cancer
- IV (Adults): Adjuvant treatment of node-positive breast cancer: 175 mg/m2 over 3 hr every 3 wk for 4 courses administered sequentially to doxorubicin-containing combination chemotherapy; Failure of initial therapy for metastatic disease or relapse within 6 mo of adjuvant therapy: 175 mg/m2 over 3 hr every 3 wk. NSCLC
- IV (Adults): 135 mg/m2 over 24 hr every 3 wk, followed by cisplatin. AIDS-Related Kaposi’s Sarcoma
- IV (Adults): 135 mg/m2 over 3 hr every 3 wk or 100 mg/m2 over 3 hr every 2 wk (dose ↓/adjustment may be necessary in patients with advanced HIV infection).
Paclitaxel Protein-Bound Particles (albumin-bound)
Breast Cancer- IV (Adults): 260 mg/m2 over 30 min every 3 wk.
Hepatic Impairment
- IV (Adults): Moderate hepatic impairment (AST levels <10 × ULN and bilirubin levels 1.51–3 × ULN): 200 mg/m2 over 30 min every 3 wk; dose may be ↑ to 260 mg/m2 for the 3rd course based on individual tolerance; Severe hepatic impairment (AST levels <10 × ULN and bilirubin levels 3.01–5× ULN): 200 mg/m2 over 30 min every 3 wk; dose may be ↑ to 260 mg/m2 for the 3rd course based on individual tolerance; Severe hepatic impairment (AST levels >10 × ULN or bilirubin levels >5 × ULN): Avoid use. NSCLC
- IV (Adults): 100 mg/m2 over 30 min on Days 1, 8, and 15 of each 21-day cycle.
Hepatic Impairment
- IV (Adults): Moderate hepatic impairment (AST levels <10 × ULN and bilirubin levels 1.51–3 × ULN): 80 mg/m2 over 30 min on Days 1, 8, and 15 of each 21-day cycle; dose may be ↑ to 100 mg/m2 for the 3rd course based on individual tolerance; Severe hepatic impairment (AST levels <10 × ULN and bilirubin levels 3.01–5 × ULN): 80 mg/m2 over 30 min on Days 1, 8, and 15 of each 21-day cycle; dose may be ↑ to 100 mg/m2 for the 3rd course based on individual tolerance; Severe hepatic impairment (AST levels >10 × ULN or bilirubin levels >5 × ULN): Avoid use. Pancreatic Adenocarcinoma
- IV (Adults): 125 mg/m2 over 30–40 min on Days 1, 8, and 15 of each 28-day cycle.
Hepatic Impairment
- IV (Adults): Moderate or severe hepatic impairment: Avoid use.